(Q40459776)

English

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

scientific article published on March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

2

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Srdan Verstovsek

6

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Jorge Eduardo Cortes

7

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Guillermo Garcia-Manero

9

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

5

object named as

Susan O'brien

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Jean-Pierre J Issa

10

object named as

Jean-Pierre J Issa

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1

object named as

Yasuhiro Oki

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Vazganush Gharibyan

3

object named as

Vazganush Gharibyan

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

8

object named as

Gail M Morris

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Dan Jones

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

109

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

899-906

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer epigenetics comes of age

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

High sensitivity mapping of methylated cytosines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Epigenetic targets in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22470

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22470

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40459776&oldid=1744043512"